The problem is they cannot afford to wait because someone else will beat them to the market. Once we have several DAA classes approved the IFN-free "party" may even start off-label (I personally don't think it will, but this just underscores the sense of urgency). And now with ABT results we know you don't really need a nuke, at least in naives, so GS-7977 is not going to become what Viread is in HIV. And without that type of monopoly power, GILD should be willing to split profits vs. risk missing them alltogether.
Market Data 
Markets 
AI
